Regeneron Pharmaceuticals, Inc. has been performing well on the stock market, with numerous bullish indicators. TD Cowen increased its price target to $1,200.00, and Price T Rowe Associates Inc. MD upped their stock holdings in Regeneron. Investors have seen significant returns, with a 220% increase seen over the past five years. They are also set to collaborate with Doudna-founded Mammoth on gene editing therapies.
However, potential risks and negative news are also present. Legal troubles and a Department of Justice price reporting complaint have put them under scrutiny, and a lymphoma candidate was rejected by the FDA. Insiders sold $26M of stock, possibly signaling weakness, caution or hesitance. Also, Q1 2024 earnings missed the expectations presenting both challenges and opportunities in the current quarter earnings.
Still, Regeneron remains an active player in the pharmaceutical industry. Positive data on its oncology candidate has been released and FDA approval for Kevzara label expansion were granted. Its CEO compensation is deemed acceptable, which can boost the company's reputation. Looking forward, analyst rates are optimistic, with one increasing the price target to $1,166.00.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 02 Nov 2023 07:00:00 GMT to Sun, 28 Jul 2024 22:55:57 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor -1
